Medicus Pharma CEO details Teverelix progress – ICYMI
Yahoo Finance · Jul 18, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study for Teverelix, reporting that the revised protocol had received Institutional Review Board approval and had been accepted by the US Food and Drug Administration subject to operational...
Not investment advice. Cached headline, not a full reprint.